大睿生物医药科技

Ribo-China is a clinical-stage biotechnology company specializing in the development of innovative RNA interference (RNAi) therapeutics. The company leverages its proprietary RIBOC™ platform, which utilizes advanced delivery technologies and chemical modifications to enhance the stability and potency of small interfering RNA (siRNA) molecules. Ribo-China's pipeline primarily focuses on metabolic, cardiovascular, and complement-mediated diseases, with lead programs targeting ANGPTL3 and Factor XI. By addressing high-unmet medical needs through liver-targeted and extra-hepatic delivery systems, the company aims to provide long-lasting and effective treatments for chronic conditions. Ribo-China is led by an experienced management team with deep expertise in oligonucleotide drug development and global clinical operations.